Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pramlintide
- Development stage
- Approved
- Lead developer
- Bristol Myers Squibb
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
Pramlintide is an amylin analog used to treat type 1 and type 2 diabetes mellitus. It works by slowing gastric emptying, reducing postprandial glucagon levels, and increasing satiety, thereby lowering blood sugar levels and aiding in weight loss. It is administered subcutaneously before meals and is used in conjunction with mealtime insulin in patients who have not achieved adequate glycemic control with insulin alone.
- Brand names
- SymlinSymlinPen 120SymlinPen120SymlinPen-120SymlinPen 60SymlinPen60SymlinPen-60
- Other names
- pramlintide acetate
02
Targets
AMY (Pancreatic alpha-amylase)GLP1R (GLP-1R)Calcitonin gene-related peptide type 1 receptorAMY3 (Amylin receptor 3)
Beyond the preview
Go deeper on pramlintide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pramlintide.